METHODS: Complete data from 2196 consecutive infertile men were analyzed. HBP was defined as blood pressure >140/90 mmHg. Comorbidities were scored with the Charlson Comorbidity Index (CCI; categorized 0 vs. 1). Semen analysis followed 2010 WHO reference criteria. Descriptive statistics tested the association between semen parameters, clinical characteristics and HBP. Clinical data of infertile men were compared with those of a homogeneous cohort of 394 agecomparable fertile men (as for WHO definition).
INTRODUCTION AND OBJECTIVES:
Data from animal studies and small trials show conflicting results regarding the effects of statins on semen quality. Evidence is even more limited in subfertile patients. We aimed to assess the effects of statin use on semen parameters. To investigate this, we retrospectively compared semen parameters in statin users vs. non-users in subfertile men.
METHODS: From 2002-2013, we reviewed data from 12257 subfertile men visited at our fertility clinic. Patients who reported using any statin drugs for >3 months before semen sample collection were identified. Data on patient age, medication use, and conventional semen parameters were extracted. 7698 subfertile men taking no medications served as controls. Patients who were using any known spermatotoxic medications were excluded from the study. Variables with non-normal distributions (concentration, total count, and total motile sperm count) were log-transformed for analyses and the corresponding coefficients were presented as ratios. Linear mixed effect regression models were used to test the effects of statin use on semen parameters adjusting for age. The model coefficients, 95% confidence intervals (CIs) and p-values were reported, and statistical significance was assessed at the 0.05 level.
RESULTS: A total of 109 patients were identified taking statins. Mean age was 38.3 (standard deviation: 7.3). Estimates from the ageadjusted regression model are presented in Table- 
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Sorena Keihani*, James R. Craig, Chong Zhang, Angela P. Presson, Jeremy B. Myers, William O. Brant, Kenneth I. Aston, Benjamin R. Emery, Douglas T. Carrell, James M. Hotaling, Salt Lake City, UT INTRODUCTION AND OBJECTIVES: Proton pump inhibitors (PPI) are among the most widely used drugs worldwide. PPI use is recently linked to adverse changes in semen quality in healthy men, however, the effects of PPI use on semen parameters remain largely unknown specifically in cases with male factor infertility. We examined whether PPI use was associated with semen parameters in a large population of subfertile men.
METHODS: We retrospectively reviewed data from 12,257 subfertile men who visited our fertility clinic between 2003 and 2013. Patients who reported using any PPIs for >3 months before semen sample collection were identified. Data were gathered on patient age, medication use, and conventional semen parameters. 7698 subfertile men taking no medications served as controls. We excluded patients who were taking any known spermatotoxic medication. Values for sperm concentration, total count, and total motile sperm count were log-transformed for analysis and corresponding coefficients were reported as ratios. Linear mixed effect regression models were used to test the effect of PPI use on semen parameters adjusting for age. The model coefficients, 95% confidence intervals (CIs) and p-values were reported, and statistical significance was assessed at the 0.05 level.
RESULTS: A total of 247 patients were identified taking PPIs, providing 258 semen samples (158 PPI only and 100 PPI plus 1 nonspermatotoxic medication). Mean age was 33.3 years (standard deviation: 6.7). Age-adjusted results from the regression model are presented in Table- 1. Overall there were no statistically significant differences in semen parameters between patients taking PPIs (+/-other medications) and controls. Similarly, there were no differences between patients taking PPIs only versus controls.
CONCLUSIONS: To our knowledge, this was the first study to compare PPI use with semen parameters in subfertile men. Using PPIs was not associated with detrimental effects on semen quality in this retrospective study. However, further studies are needed to confirm these findings. 
INTRODUCTION AND OBJECTIVES:
The male factor is implicated in approximately 50% of couples undergoing Assisted Reproductive Technology. It has been known semen alterations could be responsible for chromosomal abnormalities, poor embryonic development and repeated miscarriage.The main objective of this study was to evaluate the possible impact of oligospermia on the aneuploidy embryonic rate, comparing oligo and normospermics patients.
METHODS: This study compared 203 oligo and normospermics couples who underwent in vitro fertilization with subsequent embryo biopsy for preimplantation genetic screening (PGS) during the period from July 2014 to October 2016. The female mean age was 38.9. The seminal parameters were evaluated according to WHO 2010. Were biopsied 741 embryos. The biopsies were performed on either day 3 or day 5. The techniques used for the analysis were Array Comparative Genomic Hybridization (aCGH) or Next-Generation Sequencing (NGS). The results were analyzed by the T test (p <0.05).
RESULTS: Of the 203 patients, 40 patients (19.7%) were considered oligospermic and obtained 160 biopsied embryos. Of these, 42 (26.2%) were considered euploid embryos. Normospermics patients obtained 581 biopsied embryos, and 151 (25.9%) were considered euploid. Therefore, when considering only the seminal concentration, there is no difference between the aneuploidy embryonic rate.
CONCLUSIONS: This study showed no correlation between low seminal concentration and aneuploidy embryonic rate. Although low sperm quality is an indication for PGS, it has not yet been elucidated that there is a decrease in the rate of euploidy during in vitro fertilization as it is expected to occur with the natural conception. Therefore, it is advisable that further studies on the subject be carried out in order to corroborate these primary results. METHODS: We used the Charlson Co-Morbidity Index (CCI) to assess and compare the health status of men with abnormal sperm aneuploidy to five groups of men who received care at an academic infertility clinic: men with normal sperm ploidy (normal FISH), men with genetic abnormalities that may cause infertility (genetic infertile), men presenting for infertility with varicocele (varicocele), men with idiopathic infertility (idiopathic) and proven-fertile men. Sperm ploidy was assessed using fluorescence in situ hybridization (FISH). Genetic infertile men had proven Y chromosome microdeletions or abnormal karyotype. CCI for men with sperm FISH results was completed via telephone survey and CCI for genetic infertile men was extracted from intake forms. Men who were diagnosed with a varicocele or idiopathic infertility had not conceived after 12 months. Men with varicoceles, men with idiopathic infertility, and fertile controls completed the CCI in clinic. Fertile controls included men who presented for vasectomy and had fathered a child in the past 5 years.
RESULTS: 402 men were included in this analysis: 92 with an abnormal sperm FISH results, 7 with a normal sperm FISH test, 49 genetic infertile men, 85 men with idiopathic infertility, 86 infertile men with varicocele, and 83 fertile controls. Mean age, semen density, and CCI of all groups are described in Table 1 . Of note, malignancy was common in our cohort, exceeding rates in the SEER database for comparable age (Table 1) . Controlling for age, we explored infertility groups as a predictor of elevated CCI score, and found that only men with abnormal sperm FISH (p¼0.002) had increased risk of a higher CCI score. Age also increased the risk for a higher CCI score, with each additional year raising the CCI by 0.0117 points (p¼0.009).
CONCLUSIONS: Men with elevated sperm aneuploidy have nearly double the prevalence of general health issues, particularly malignancy, when compared with men with infertility of other etiologies. These findings further support the relationship between genetic causes of male infertility and general health.
